Suchergebnisse - "Gupta, Neeraj"

PubPharm (32)

1

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

enthalten in: Journal of clinical pharmacology | 2023

von Hanley, M. | D'Arcangelo, M. | Felip, E. | +5

2

A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Kim, R. | Leal, A. | Parikh, A. | +9

ErratumIn: Cancer Chemother Pharmacol. 2023 Mar 26;:. - PMID 36967405

3

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

enthalten in: Expert review of anticancer therapy | 2023

von Yang, J. | Zhou, C. | Jänne, P. | +18

4

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

5

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions : Exposure-Response Analyses of a Pivotal Phase I/II Study

enthalten in: Clinical pharmacology and therapeutics | 2022

von Gupta, N. | Largajolli, A. | Witjes, H. | +5

6

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Gupta, N. | Pierrillas, P. | Hanley, M. | +2

7

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

enthalten in: Journal of clinical pharmacology | 2022

von Zhou, X. | Ouerdani, A. | Diderichsen, P. | +1

8

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

enthalten in: Targeted oncology | 2022

von Shimizu, T. | Kuboki, Y. | Lin, C. | +7

ErratumIn: Target Oncol. 2022 Apr 12;:. - PMID 35412171

9

Effect of severe renal impairment on the pharmacokinetics of brigatinib

enthalten in: Investigational new drugs | 2021

von Gupta, N. | Hanley, M. | Kerstein, D. | +4

10

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2021

von Zhang, S. | Jin, S. | Griffin, C. | +4